Analyst Price Target is $6.33
▲ +441.31% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Outlook Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 441.31% upside from the last price of $1.17.
Current Consensus is
Buy
The current consensus among 4 investment analysts is to buy stock in Outlook Therapeutics. This Buy consensus rating has held steady for over two years.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Read More